Lilly’s Foundayo Shows Strong Weight Loss Across Menopause
INDIANAPOLIS, Indiana, June 7, 2026 Eli Lilly and Company has announced new data demonstrating that Foundayo® (orforglipron), the only...
Cardiometabolic health
Advertisement
Ascletis Showcases Next-Generation Obesity Pipeline at ADA 2026
HONG KONG and NEW ORLEANS, Louisiana, June 8, 2026 Ascletis Pharma has strengthened its position in the highly competitive...
Berobenatide Shows Strong Weight Loss With Monthly Dosing
NEW ORLEANS, Louisiana, June 6, 2026 New data presented at the American Diabetes Association (ADA) 2026 Scientific Sessions have...
Jazz Highlights New Xywav Data Across Narcolepsy and Idiopathic Hypersomnia
DUBLIN, Ireland, June 4, 2026 Jazz Pharmaceuticals has announced the presentation of an extensive portfolio of new clinical and...
Novo Nordisk Launches Wegovy Pill in UAE Market
BAGSVÆRD, Denmark, June 3, 2026 Novo Nordisk has announced the launch of Wegovy® pill (semaglutide tablets) in the United...
Advertisements
Lilly Unveils Landmark Phase 3 Data for Foundayo and Retatrutide at ADA 2026
INDIANAPOLIS, May 28, 2026 Eli Lilly and Company has announced a major slate of scientific presentations for the American...
Eli Lilly Retatrutide Phase 3 Trial Delivers Major Weight Loss
INDIANAPOLIS, May 21, 2026 Eli Lilly and Company announced positive topline results from its pivotal Phase 3 TRIUMPH-1 clinical...
Eli Lilly Strengthens GLP-1 Leadership With New Foundayo Trial Results
INDIANAPOLIS, May 12, 2026 Eli Lilly and Company has reported positive results from two major late-phase obesity trials showing...
Lilly’s Oral GLP-1 Orforglipron Delivers Strong Phase 3 Results in Type 2 Diabetes
INDIANAPOLIS, Oct. 15, 2025 — Eli Lilly and Company (NYSE: LLY) announced positive topline results from two pivotal Phase...
Pfizer Expands Obesity Pipeline with $4.9B Metsera Acquisition
NEW YORK, September 22, 2025 – In a landmark move shaping the future of obesity and cardiometabolic disease treatments,...
Advertisement
